risedronate sodium · RISEDRONATE SODIUM HEMI-PENTAHYDRATE 35 mg/1 · Tablet, Film Coated · Oral · Sun Pharmaceutical Industries, Inc.
NDC 47335-0668-62 · 3 BLISTER PACK in 1 CARTON / 4 TABLET, FILM COATED in 1 BLISTER PACK · ANDA · View full market →
10 companies supply this market — deep enough that no single failure threatens the supply. The price is down 9% over the past year, to $2.01 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Aurobindo Pharma Limited | RISEDRONATE SODIUM 5 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Aurobindo Pharma Limited | RISEDRONATE SODIUM 35 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Allergan, Inc. | RISEDRONATE SODIUM HEMIPENTAHYDRATE 129 mg/1; RISEDRONATE SODIUM MONOHYDRATE 21 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | RISEDRONATE SODIUM HEMI-PENTAHYDRATE 30.1 mg/1; RISEDRONATE SODIUM MONOHYDRATE 4.9 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | RISEDRONATE SODIUM HEMIPENTAHYDRATE 30.1 mg/1; RISEDRONATE SODIUM MONOHYDRATE 4.9 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | RISEDRONATE SODIUM HEMI-PENTAHYDRATE 129 mg/1; RISEDRONATE SODIUM MONOHYDRATE 21 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Apotex Corp. | RISEDRONATE SODIUM 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Apotex Corp. | RISEDRONATE SODIUM 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Apotex Corp. | RISEDRONATE SODIUM 35 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | RISEDRONATE SODIUM 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hangzhou Minsheng Binjiang Pharmaceutical CO., Ltd | RISEDRONATE SODIUM HEMI-PENTAHYDRATE 35 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | RISEDRONATE SODIUM 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | RISEDRONATE SODIUM 35 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | RISEDRONATE SODIUM 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals, Inc. | RISEDRONATE SODIUM HEMIPENTAHYDRATE 30.1 mg/1; RISEDRONATE SODIUM MONOHYDRATE 4.9 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals, Inc. | RISEDRONATE SODIUM HEMIPENTAHYDRATE 129 mg/1; RISEDRONATE SODIUM MONOHYDRATE 21 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pel Healthcare Llc | RISEDRONATE SODIUM MONOHYDRATE 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Proficient Rx LP | RISEDRONATE SODIUM 35 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | RISEDRONATE SODIUM HEMI-PENTAHYDRATE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | RISEDRONATE SODIUM HEMI-PENTAHYDRATE 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | RISEDRONATE SODIUM HEMI-PENTAHYDRATE 35 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | RISEDRONATE SODIUM HEMI-PENTAHYDRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | RISEDRONATE SODIUM HEMI-PENTAHYDRATE 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | RISEDRONATE SODIUM MONOHYDRATE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | RISEDRONATE SODIUM MONOHYDRATE 35 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Teva Pharmaceuticals USA, Inc. | RISEDRONATE SODIUM MONOHYDRATE 5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | RISEDRONATE SODIUM 30 mg/1 | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "risedronate sodium — NDC 47335-0668-62," retrieved September 3, 2026, https://drugdashboards.com/drug/47335066862.
Free to cite with attribution — see how the data is put together.